Answers are grounded in this paper and cite their sources.
Three-dimensional (3D) bioprinting technology offers a transformative approach for constructing biomimetic tumor organoid models that overcome the limitations of traditional two-dimensional cell cultures and animal models. This review systematically summarizes recent advances in 3D bioprinted tumor organoids, emphasizing extrusion-based, inkjet-based, and lithography-based bioprinting methods. These technologies enable precise spatial control of cell distribution and tissue architecture, achieving high reproducibility while maintaining complex tumor microenvironmental characteristics. Applications across multiple cancer types—including colorectal, gastric, pancreatic, breast, glioma, renal, bladder, lung, and thyroid cancers—demonstrate significant potential for drug screening, tumor heterogeneity research, and preclinical evaluation of individualized treatment responses. Despite substantial progress, challenges remain regarding multicellular complexity simulation, technical resolution, and biomaterial optimization. Future directions include integrating four-dimensional bioprinting, multiomics analysis, and immune microenvironment reconstruction to enhance physiological fidelity and clinical applicability, ultimately advancing precision oncology and personalized cancer treatment strategies.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: